Marisa Wexler, MS,  senior science writer—

Intellia Therapeutics and ReCode Therapeutics are joining forces to develop new genomic medicines for people with cystic fibrosis (CF). The companies said initial research will focus on patients who have “limited or no treatment options available.” The ultimate goal is to create a new genomic medicine that…

The frequent use of aminoglycosides — a class of antibiotics commonly used to help treat lung infections in people with cystic fibrosis (CF) — has been linked to an increased risk of hearing problems in CF patients, starting in childhood, according to a new pediatric study in Belgium. The…

A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor — outperformed the approved therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) at reducing sweat chloride levels in Phase 3 trials. The new “vanza triple” combo was similar to Trikafta at maintaining…

Enterprise Therapeutics has raised £26 million (nearly $33 million USD) in series B financing, which the company is planning to use to fund a Phase 2a clinical trial of EDT001, its experimental treatment for cystic fibrosis (CF). The upcoming trial is expected to enroll people with CF who…

Treatment with SPI-1005 in adults with cystic fibrosis (CF) appeared to lessen the risk of ear damage related to antibiotics use — widely prescribed for treating lung infections in CF patients — in a Phase 2 clinical trial. That’s according to new interim data from the STOP study…

The eighth annual BreatheCon, a virtual event hosted by the Cystic Fibrosis Foundation that brings together adults with cystic fibrosis (CF), is coming up Feb. 9-10. BreatheCon 2024 will focus on the individual experience of the CF journey. Participants will have opportunities to share their own stories,…

Results of three global clinical trials of a new triple-combination CFTR modulator therapy for cystic fibrosis (CF) —  vanzacaftor, tezacaftor and deutivacaftor — are expected shortly, Vertex Pharmaceuticals, the therapy’s developer, announced. Two of these Phase 3 trials, SKYLINE 103 (NCT05076149) and SKYLINE 102 (NCT05033080), which tested the…

Treatment with the inhaled antibiotic aztreonam can stabilize lung function in people with cystic fibrosis (CF) who have chronic infections of the bacterium Pseudomonas aeruginosa. That’s according to “Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness,”…

People with cystic fibrosis (CF) who have chronic inflammation in the nose are less likely to need sinus surgery if they are taking the triple-combination CFTR modulator treatment Kaftrio (elexacaftor/tezacaftor/ivacaftor). That’s according to “Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery…

Inflammatory molecules that serve as markers of infection or other problems can be measured in the nasal fluid of babies with cystic fibrosis (CF), collected using filter paper placed in a nostril. Changes in the levels of some of these molecules, using this noninvasive method, were seen in infants…